You are here: Industry Insights > Market News

News List

InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines PR Newswire
February 12, 2025
Partnership taps real-world data to accelerate clinical trials and drug development in Japan.
Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases PharmaSources
October 15, 2024
Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.
Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
Professor James Rothman, Nobel Laureate, to Join the Board of Noscendo GmbH Biotech Newswire
August 21, 2024
Noscendo GmbH announced that Professor James Rothman has agreed to serve on its board as an independent director.
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024
Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.
Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024 PharmaSources
August 26, 2024
Avantor, Inc. has secured three prestigious awards at the esteemed Korea Biopharma Excellence Awards (KBEA) 2024.
Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus Biotech Newswire
August 22, 2024
Touchlight announced the clinical supply of its proprietary dbDNA™ to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus.